Merck KGaA, Darmstadt, Germany, partners with Medisafe to help improve medication adherence for Cardiometabolic Patients
- Collaboration to help thousands of patients with chronic conditions to manage their medication intake and improve adherence to treatment
- Merck KGaA, Darmstadt, Germany, continues to strengthen its Primary Care portfolio with additional digital offering
- Brazil, Russia and Mexico among the first countries to benefit from this initiative
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens. In the countries of scope Merck KGaA, Darmstadt, Germany, patients will have access to a customized version of Medisafe´s mobile platform that could combine reminders, motivation and support systems, targeted content, coupons and interventions in their local language.
“This is an extremely important step towards realizing our vision of supporting patients with comprehensive, integrated, value-added services that look beyond medicines to improve treatment outcomes. We are confident that offering such a solution to our patients has the potential to significantly improve medication adherence by giving patients and carers the tools to organize, understand and manage their medications” said Simon Sturge, Chief Operating Officer at Merck KGaA, Darmstadt, Germany, Biopharma business.
Medisafe is a leading medication management and adherence solution in which M Ventures has invested in, which has been named top app for medication management by November 2017 IQVIA (Quintiles IMS) report. It has received endorsements from the American Pharmacy Association, Journal of Medical Internet Research (JMIR), and Ranked Health. Medisafe has already delivered high rates of adherence across multiple disease areas, and recorded significant improvements - notably, 86% of Stage 2 hypertensive users reduced their risk category to Stage 1 or below.1
This digital solution will complement Merck KGaA, Darmstadt, Germany´s, current offering of Primary Care medicines for cardiometabolic conditions, which includes treatments for type 2 diabetes, thyroid disorders, and cardiovascular diseases. Although many medications are effective in combating chronic diseases, their full benefits are often not realized by the patients. Approximately 50% of patients do not adhere to long-term therapies,2,3 and this percentage is much higher in developing countries.3 A systematic review of anti-diabetic therapies found wide-ranging adherence rates between 36% to 93%.4 This is of great concern when adherence to medication is critical to positive outcomes.
Factors contributing to poor medication adherence are myriad and include those that are related to patients, physicians and healthcare systems, so improving adherence requires a continuous and dynamic process.3 Because of this complex matrix of factors, our knowledge of the underlying causes of poor medication adherence is still very limited. The collaboration with Medisafe offers the possibility to reveal new overall insights into patient behaviors through aggregated and de-identified data collected by Medisafe, which may contribute to improved chronic disease management in the future.
Brazil, Russia and Mexico are the first three countries where patients receiving the company´s primary care medicines will have access to a customized version of Medisafe. Globally, around 60 million patients with chronic conditions are estimated to be treated with Merck KGaA, Darmstadt, Germany medications daily.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO (contract testing, development and manufacturing organization) to offer integrated services